April 2008, Vol 1, No 3

Regulatory

Medicare Coverage Policies for Biologics: The Broad Gray Line
Part 2 of an Interview with Joseph Antos, PhD
Stakeholder Perspective by Michael F. Murphy, MD, PhD

Business

Benchmarking New Frontiers in Managed Care Pharmacy
Cynthia Pigg, BSPharm, MHA
; Joan Cihak, MSS, MHA
Stakeholder Perspective by F. Randy Vogenberg, RPh, PhD
Not Waiting for Godot: The Evolution of Health Promotion at PPG Industries
Alberto M. Colombi, MD, MPH
; Janice L. Pringle, PhD
; George T. Welsh, BS, MBA
Stakeholder Perspective by F. Randy Vogenberg, RPh, PhD

Clinical

Meta-Analysis 101: What You Want to Know in the Era of Comparative Effectiveness
J. B. Jones, PhD, MBA
; Saul Blecker, MD
; Nirav R. Shah, MD, MPH
Stakeholder Perspective by Scott R. Taylor, RPh, MBA
Depression Overview
Thomas McCarter, MD, FACP

Editorial

The Great P Value: We the People
Robert E. Henry
The Health Reform in America
Uwe Reinhardt, PhD

Generic Drug Trends

Seizing the Opportunity
Gary M. Owens, MD

FDA Watch

Regulatory Concerns Fuel Hunger in Congress for FDA Reform
Mark Senak, JD